- Home
- UOKA vs SCNI Comparison
UOKA vs SCNI Comparison
Compare UOKA & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UOKA
- SCNI
- Stock Information
- Founded
- UOKA 2002
- SCNI 2003
- Country
- UOKA United Kingdom
- SCNI Israel
- Employees
- UOKA 11
- SCNI N/A
- Industry
- UOKA
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UOKA
- SCNI Health Care
- Exchange
- UOKA NYSE
- SCNI Nasdaq
- Market Cap
- UOKA 2.9M
- SCNI 3.0M
- IPO Year
- UOKA N/A
- SCNI N/A
- Fundamental
- Price
- UOKA $0.19
- SCNI $3.54
- Analyst Decision
- UOKA
- SCNI
- Analyst Count
- UOKA 0
- SCNI 0
- Target Price
- UOKA N/A
- SCNI N/A
- AVG Volume (30 Days)
- UOKA 19.5M
- SCNI 6.9K
- Earning Date
- UOKA 02-16-2025
- SCNI 11-22-2024
- Dividend Yield
- UOKA N/A
- SCNI N/A
- EPS Growth
- UOKA N/A
- SCNI N/A
- EPS
- UOKA N/A
- SCNI 8.20
- Revenue
- UOKA $114,849.00
- SCNI $452,000.00
- Revenue This Year
- UOKA N/A
- SCNI N/A
- Revenue Next Year
- UOKA N/A
- SCNI N/A
- P/E Ratio
- UOKA N/A
- SCNI $0.43
- Revenue Growth
- UOKA 289.97
- SCNI N/A
- 52 Week Low
- UOKA $0.13
- SCNI $2.23
- 52 Week High
- UOKA $1.90
- SCNI $8.92
- Technical
- Relative Strength Index (RSI)
- UOKA N/A
- SCNI 51.37
- Support Level
- UOKA N/A
- SCNI $3.45
- Resistance Level
- UOKA N/A
- SCNI $3.61
- Average True Range (ATR)
- UOKA 0.00
- SCNI 0.12
- MACD
- UOKA 0.00
- SCNI -0.00
- Stochastic Oscillator
- UOKA 0.00
- SCNI 32.31
About UOKA MDJM LTD
MDJM Ltd is a real estate service company. The company provides real estate agency services to real estate developer clients, as well as real estate consulting services and independent training services on an as-needed basis. It offers consulting, marketing planning, advertising services, and sales strategies to real estate clients. The company income is derived from commission-based services and minimal consulting and other services. The company has two operating segments; the real estate agent services segment and the hospitality business segment. It derives a majority of its revenue from the People's Republic of China.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.